Topic resource collection
Approved comparison material connected to this topic.
774 resourcesRead both sides
BPC-157 NF-kB inhibition, VEGF upregulation, nitric oxide stabilisation Chronic widespread pain, inflammation, tissue hypoxia 200–500 mcg/day subcutaneous Preclinical models + case series Strongest anti-inflammatory profile. Addr…
Thymalin Thymic immune modulation Treg upregulation reduces anti-TPO antibodies in Hashimoto's Phase 2 trials (Eastern Europe) 10–30 mg IM every other day for 10 doses Effective for early-stage autoimmune thyroiditis; requires re…
This table compares the leading research peptides for Parkinson's disease based on mechanism, administration route, evidence quality, and practical considerations. Cerebrolysin Delivers neurotrophic factors (BDNF, NGF, CNTF) that…
Before selecting a peptide protocol, compare mechanism of action, administration requirements, and the specific FET challenge each addresses. Thymalin T-regulatory cell expansion, immune tolerance 10mg SC daily × 10 days 10–12 da…
Before designing a peptide stack, understand how compound classes interact and where they belong in a protocol hierarchy. GH Secretagogues (CJC-1295/Ipamorelin) GHRH/ghrelin receptor agonism → pulsatile GH release 3–5×/week (CJC …
Thymalin T-cell modulation; Treg upregulation Moderate (Eastern European clinical trials) 5–10mg subcutaneous, 2–3 times weekly 22–34% reduction in anti-TPO titres over 12 weeks in 2018 study Strongest evidence for immune recalib…
This table compares the mechanisms, clinical evidence, and practical considerations for peptides with documented or theoretical stroke-prevention effects. Cerebrolysin Neurotrophic factor mimetic (BDNF, NGF pathways) 6 RCTs in ac…
BPC-157 Inhibits NF-κB inflammatory pathway; promotes vascular repair Strong. Multiple tissue injury models show reduced inflammation and accelerated healing 250–500 mcg subcutaneous daily Minimal adverse effects reported; no hum…
The table below compares the three peptides with the strongest published evidence for scar healing based on mechanism, clinical trial data, application method, and observed outcomes. BPC-157 VEGF upregulation, NO pathway activati…
Thymosin Beta-4 Actin sequestration, VEGF upregulation, urothelial regeneration Epithelial damage, barrier dysfunction, IC Strong preclinical (mouse, rat models); Phase I human trials underway Subcutaneous injection Best evidence…
BPC-157 VEGF-R2 upregulation → angiogenesis, collagen synthesis Subcutaneous peri-wound or topical 250–500 mcg/day or every other day Preclinical + case reports Best for wounds with poor granulation tissue and low vascularity. Ta…
LL-37 (Cathelicidin) Direct antimicrobial activity via bacterial membrane disruption MIC against E. coli and Enterococcus at 2–8 μg/mL; SIBO patients show 58% reduced LL-37 expression Not available as exogenous peptide; upregulat…
Dihexa HGF receptor agonist; stimulates synaptogenesis in prefrontal cortex 40–60% oral; crosses BBB efficiently 0.25–2mg daily, oral or subcutaneous Increased synaptic density 300% in rodent PFC; sustained cognitive benefit 4 we…
BPC-157 VEGF upregulation, angiogenesis, collagen organization 200–500mcg daily, 4–6 weeks Proliferative (days 7–21) Rat tendon models: 60% faster tensile strength recovery (Journal of Orthopaedic Research, 2019) Best for hypovas…
| Peptide | Primary Mechanism | Lupus-Relevant Pathway | Studied Dosage Range | Half-Life | Bottom Line ||—|—|—|—|—|| Thymalin | Thymic T-cell regulation | Restores central tolerance; reduces autoreactive T-cell activation | 5–20…
Conservative (PT + NSAIDs) Symptom management, no tissue repair 6–12 weeks (if effective) None. Relies on existing blood supply High (55% remain symptomatic) Does not address avascularity; effective only for minor peripheral tear…
Thymalin T-regulatory cell differentiation via thymulin receptor activation CD4+ T-cells in thymic tissue and peripheral circulation Minimal. Acts systemically on immune organs, not CNS-direct 10–30mg SC daily, 10-day cycles Shor…
| Peptide | Primary Mechanism | Tissue Target | Evidence Level | Typical Research Dose | Administration Route | Professional Assessment ||—|—|—|—|—|—|| BPC-157 | VEGF upregulation, nitric oxide modulation | Esophageal mucosa, gas…
Lactotripeptides (VPP, IPP) ACE inhibition 2.6–7.5mg/day −3.7 / −2.0 mmHg (sys/dia) High. 18 RCTs, 1,060 participants Best-characterized oral peptides; consistent modest effect in mild hypertension Marine Collagen Hydrolysate eNO…
Cerebrolysin Neurotrophic factor mix (BDNF, NGF, CNTF) TrkB receptor → PI3K/Akt, MAPK/ERK → synaptic protein upregulation 20+ RCTs in schizophrenia (1995–2026); strongest evidence for negative symptom reduction and working memory…